Following the International Myeloma Working Group criteria, we usually check for minimal residual disease when the patient has reached a complete remission or is very close to complete remission, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Following the International Myeloma Working Group criteria, we usually check for minimal residual disease when the patient has reached a complete remission or is very close to complete remission, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Transcript
At what point after treatment should patients with multiple myeloma have an MRD assessment?
Well, usually we check for minimal residual disease when the patient has reached a complete remission or is very close to complete remission. So, right now the International Myeloma Working Group criteria say that you would check for this when the patients have complete remission, and you can do this by flow cytometry or sequencing—whatever is available at your institution. You don't have to choose 1 over the other. You do have to be aware of the sensitivity of the assay–there are different sensitivities depending on the number of cells that you analyze from the bone marrow. So, that's basically what you need to know.
Now if the patient is MRD negative, you may want to recheck that. There is a category in the response which is sustained MRD negativity, which does say that at 1-year intervals, the patient remains negative. So, if you want to do the assessment once the patient has reached the complete remission, and if the patient is negative, you want to check again maybe in a year. If the patient is still negative after 1 or 2 years, you can say that the patient is in the sustained minimal residual disease negative zone category in the response criteria for multiple myeloma.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More